Clinical Trial Update: Regulation of Arginine-vasopressin (AVP) [NA]

View source ↗

Summary

Completed Yale-sponsored clinical trial studying the regulation of arginine-vasopressin (AVP) in schizophrenia and depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Schizophrenia

Snippet

Sponsor: Yale University | Conditions: Schizophrenia, Depression | NA | Status: COMPLETED